Limited Competition: Sickle Africa Data Coordinating Center (U24 Clinical Trial Optional)
Funding Opportunity RFA-HL-21-008 from the NIH Guide for Grants and Contracts. This limited competition Funding Opportunity Announcement (FOA) seeks an application from the current Sickle Africa Data Coordinating Center (SADaCC) to continue support of the activities of the renewed and expanded Sickle Pan-African Research Consortium (SPARCO), including the clinical coordinating center (CCC) in Tanzania, the 3 established sites in Ghana, Nigeria and Tanzania (and additional satellite sites), as well as up to 3 new Consortium sites located in additional sub-Saharan African nations. Together, these entities will constitute ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 12, 2020 Category: Research Source Type: funding
Limited Competition: Sickle Pan-African Research Consortium Clinical Coordinating Center (U24 Clinical Trial Optional)
Funding Opportunity RFA-HL-21-007 from the NIH Guide for Grants and Contracts. This limited competition Funding Opportunity Announcement (FOA) seeks an application from the current Sickle Pan-African Research Consortium (SPARCO) Hub in Tanzania to continue coordinating, as the Clinical Coordinating Center (CCC), activities of the renewed and expanded Consortium (SPARCO), including the 3 established sites in Ghana, Nigeria and Tanzania as well as up to 3 new Consortium sites located in additional sub-Saharan African nations. Together, the CCC, the Sickle Africa Data Coordinating Center (SADaCC, see RFA-HL-21-008), as wel...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 12, 2020 Category: Research Source Type: funding
Fertility and Fertility Preservation for Patients with Diseases that Previously Precluded Reproduction (R21 Clinical Trial Optional)
Funding Opportunity RFA-HD-20-021 from the NIH Guide for Grants and Contracts. The purpose of this RFA is to encourage studies on reproductive health, fertility and fertility preservation/treatment options in patients born with a serious chronic condition who can now expect to survive into adulthood healthy enough to consider their reproductive health and fertility options. The underlying pathophysiology of diseases such as sickle cell anemia, thalassemia, and cystic fibrosis, among others, and/or the cumulative effects of their treatment, can compromise reproductive health. This RFA encourages teams of scientists with ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 12, 2019 Category: Research Source Type: funding
Rare Disease Cohorts in Heart, Lung, Blood and Sleep Disorders (UG3/UH3 Clinical Trial Not Allowed)
Funding Opportunity RFA-HL-20-014 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to fund research centers that will establish longitudinal cohorts in rare HLBS diseases to investigate unaddressed research questions using epidemiologic study designs and methods that are appropriate for conditions affecting fewer than 200,000 persons in the US. These observational cohort studies should be designed to provide an evidence base for future interventional studies, including clinical trials; for developing better diagnostics than those that are currently available; for answering early translational ques...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 4, 2019 Category: Research Source Type: funding
BLOODSAFE: Research to enhance availability of safe blood for patients with severe anemia and hemorrhagic conditions in low or lower-middle income countries (LLMICs) in Sub-Saharan Africa (UG3/UH3 Clinical Trial Optional)
Funding Opportunity RFA-HL-20-009 from the NIH Guide for Grants and Contracts. This funding opportunity announcement will supportprojectsto enhance the availability and delivery of safe blood to be used for transfusion in patients from low or lower-middle income countries (LLMICs) in Sub-Saharan Africa (SSA). For example, ensuring that children with malaria or sickle cell disease and pregnant women who suffer from obstetric hemorrhage have access to safe transfusion therapies is of high programmatic interest. BLOODSAFE will support projects that develop and test feasible, effective and sustainable strategies to increase...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 11, 2019 Category: Research Source Type: funding
Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-NS-18-043 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studi...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 19, 2018 Category: Research Source Type: funding
Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This wi...
Source: NIDDK Funding Opportunities - September 19, 2018 Category: Endocrinology Source Type: funding
Addressing Health Disparities in NIDDK Diseases (R01 - Clinical Trial Not Allowed)
Funding Opportunity PA-18-412 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites research to understand and mitigate health disparities in the development, diagnosis, and treatment of diseases of high priority to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Research is encouraged in the following high priority diseases: diabetes and other endocrine and metabolic diseases; obesity; nutrition-related disorders; hepatitis C; gallbladder disease; H. Pylori infection; complications of sickle cell disease within the NIDDK mission areas; kidney dise...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 17, 2017 Category: Research Source Type: funding
Addressing Health Disparities in NIDDK Diseases (R01 - Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites research to understand and mitigate health disparities in the development, diagnosis, and treatment of diseases of high priority to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Research is encouraged in the following high priority diseases: diabetes and other endocrine and metabolic diseases; obesity; nutrition-related disorders; hepatitis C; gallbladder disease; H. Pylori infection; complications of sickle cell disease within the NIDDK mission areas; kidney diseases; urologic diseases; metabolic, gastrointestinal, hepatic, and renal compl...
Source: NIDDK Funding Opportunities - November 17, 2017 Category: Endocrinology Source Type: funding
Sickle Cell Disease Treatment Demonstration Regional Collaboratives Program
Funding Opportunity ID: 290038 Opportunity Number: HRSA-17-078 Opportunity Title: Sickle Cell Disease Treatment Demonstration Regional Collaboratives ProgramOpportunity Category: DiscretionaryOpportunity Category Explanation: Funding Instrument Type: Cooperative AgreementCategory of Funding Activity: HealthCategory Explanation: https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=c6084989-3725-4b51-b309-206698402829CFDA Number(s): 93.365Eligible Applicants: Others (see text field entitled "Additional Information on Eligibility" for clarification)Additional Informati...
Source: Grants.gov - February 19, 2017 Category: Research Tags: Health Source Type: funding
Sickle Cell Disease Treatment Demonstration Regional Collaboratives Program
Funding for Regional Coordinating Centers (RCC) that will establish regional networks and provide leadership and support for regional and statewide activities that will develop and establish systemic mechanisms to improve the prevention and treatment of sickle cell disease. Geographic coverage: Nationwide -- Maternal and Child Health Bureau (Source: Funding opportunities via the Rural Health Information Hub)
Source: Funding opportunities via the Rural Health Information Hub - November 16, 2016 Category: American Health Source Type: funding
Sickle Cell Disease Treatment Demonstration Regional Collaboratives Program
Funding Opportunity ID: 290038 Opportunity Number: HRSA-17-078 Opportunity Title: Sickle Cell Disease Treatment Demonstration Regional Collaboratives ProgramOpportunity Category: DiscretionaryOpportunity Category Explanation: Funding Instrument Type: Cooperative AgreementCategory of Funding Activity: HealthCategory Explanation: https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=c6084989-3725-4b51-b309-206698402829CFDA Number(s): 93.365Eligible Applicants: Others (see text field entitled "Additional Information on Eligibility" for clarification)Additional Informati...
Source: Grants.gov - November 10, 2016 Category: Research Tags: Health Source Type: funding
Addressing Health Disparities in NIDDK Diseases (R01)
This Funding Opportunity Announcement (FOA) invites research projects to improve understanding of the causes of high priority diseases in the United States and reducing/eliminating health disparities. Research is encouraged in the following high priority diseases within the scientific mission areas of the NIDDK: diabetes; obesity; nutrition-related disorders; hepatitis C; gallbladder disease; H. Pylori infection; sickle cell disease, specifically, studies in complications of sickle cell disease within the NIDDK mission areas; kidney diseases; urologic diseases; hematologic diseases, including studies in abnormal hemoglobin...
Source: NIDDK Funding Opportunities - October 19, 2016 Category: Endocrinology Source Type: funding
Sickle Cell Disease Newborn Screening Follow-Up Program
Funding Opportunity ID: 288736 Opportunity Number: HRSA-17-079 Opportunity Title: Sickle Cell Disease Newborn Screening Follow-Up ProgramOpportunity Category: DiscretionaryOpportunity Category Explanation: Funding Instrument Type: Cooperative AgreementCategory of Funding Activity: HealthCategory Explanation: https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fCycleID=f3f0739a-466d-434a-ab53-4f266b114cb6CFDA Number(s): 93.110Eligible Applicants: Others (see text field entitled "Additional Information on Eligibility" for clarification)Additional Information on Eligibility: ...
Source: Grants.gov - September 10, 2016 Category: Research Tags: Health Source Type: funding
